The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway

Hiroyoshi Kurihara, Reo Maruyama, Kazuya Ishiguro, Shinichi Kanno, Itaru Yamamoto, Keisuke Ishigami, Kei Mitsuhashi, Hisayoshi Igarashi, Miki Ito, Tokuma Tanuma, Yasutaka Sukawa, Kenji Okita, Tadashi Hasegawa, Kohzoh Imai, Hiroyuki Yamamoto, Yasuhisa Shinomura, Katsuhiko Nosho

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

Polycomb group protein enhancer of zeste homolog 2 (EZH2) is a methyltransferase that correlates with the regulation of invasion and metastasis and is overexpressed in human cancers such as colorectal cancer. MicroRNA-31 (miR-31) plays an oncogenic role and is associated with BRAF mutation and poor prognosis in colorectal cancer. EZH2 is functionally considered to suppress miR-31 expression in human cancers; however, no study has reported its relationship with colon cancer. We therefore evaluated EZH2 expression using immunohistochemistry and assessed miR-31 and epigenetic alterations using 301 colorectal carcinomas and 207 premalignant lesions. Functional analysis was performed to identify the association between EZH2 and miR-31 using cancer cell lines. In the current study, negative, weak, moderate, and strong EZH2 expressions were observed in 15%, 19%, 25%, and 41% of colorectal cancers, respectively. EZH2 was inversely associated with miR-31 (P <0.0001), independent of clinicopathological and molecular features. In a multivariate stage-stratified analysis, high EZH2 expression was related to favorable prognosis (P = 0.0022). Regarding premalignant lesions, negative EZH2 expression was frequently detected in sessile serrated adenomas/polyps (SSA/Ps) (76%; P <0.0001) compared with hyperplastic polyps, traditional serrated adenomas, and non-serrated adenomas (25-36%). Functional analysis demonstrated that the knockdown of EZH2 increased miR-31 expression. In conclusion, an inverse association was identified between EZH2 and miR-31 in colorectal cancers. Our data also showed that upregulation of EZH2 expression may be rare in SSA/Ps. These results suggest that EZH2 suppresses miR-31 in colorectal cancer and may correlate with differentiation and evolution of serrated pathway.

Original languageEnglish
Pages (from-to)12704-12717
Number of pages14
JournalOncotarget
Volume7
Issue number11
DOIs
Publication statusPublished - 2016 Mar 15
Externally publishedYes

Fingerprint

MicroRNAs
Colorectal Neoplasms
Adenoma
Polyps
Enhancer of Zeste Homolog 2 Protein
Polycomb-Group Proteins
Neoplasms
Methyltransferases
Epigenomics
Colonic Neoplasms
Up-Regulation
Immunohistochemistry
Neoplasm Metastasis
Cell Line
Mutation

Keywords

  • ChIP
  • CIMP
  • EGFR
  • EZH2
  • H3K27me3

ASJC Scopus subject areas

  • Oncology

Cite this

Kurihara, H., Maruyama, R., Ishiguro, K., Kanno, S., Yamamoto, I., Ishigami, K., ... Nosho, K. (2016). The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway. Oncotarget, 7(11), 12704-12717. https://doi.org/10.18632/oncotarget.7260

The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway. / Kurihara, Hiroyoshi; Maruyama, Reo; Ishiguro, Kazuya; Kanno, Shinichi; Yamamoto, Itaru; Ishigami, Keisuke; Mitsuhashi, Kei; Igarashi, Hisayoshi; Ito, Miki; Tanuma, Tokuma; Sukawa, Yasutaka; Okita, Kenji; Hasegawa, Tadashi; Imai, Kohzoh; Yamamoto, Hiroyuki; Shinomura, Yasuhisa; Nosho, Katsuhiko.

In: Oncotarget, Vol. 7, No. 11, 15.03.2016, p. 12704-12717.

Research output: Contribution to journalArticle

Kurihara, H, Maruyama, R, Ishiguro, K, Kanno, S, Yamamoto, I, Ishigami, K, Mitsuhashi, K, Igarashi, H, Ito, M, Tanuma, T, Sukawa, Y, Okita, K, Hasegawa, T, Imai, K, Yamamoto, H, Shinomura, Y & Nosho, K 2016, 'The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway', Oncotarget, vol. 7, no. 11, pp. 12704-12717. https://doi.org/10.18632/oncotarget.7260
Kurihara, Hiroyoshi ; Maruyama, Reo ; Ishiguro, Kazuya ; Kanno, Shinichi ; Yamamoto, Itaru ; Ishigami, Keisuke ; Mitsuhashi, Kei ; Igarashi, Hisayoshi ; Ito, Miki ; Tanuma, Tokuma ; Sukawa, Yasutaka ; Okita, Kenji ; Hasegawa, Tadashi ; Imai, Kohzoh ; Yamamoto, Hiroyuki ; Shinomura, Yasuhisa ; Nosho, Katsuhiko. / The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway. In: Oncotarget. 2016 ; Vol. 7, No. 11. pp. 12704-12717.
@article{2acaf074daa24765ac1407232189fb72,
title = "The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway",
abstract = "Polycomb group protein enhancer of zeste homolog 2 (EZH2) is a methyltransferase that correlates with the regulation of invasion and metastasis and is overexpressed in human cancers such as colorectal cancer. MicroRNA-31 (miR-31) plays an oncogenic role and is associated with BRAF mutation and poor prognosis in colorectal cancer. EZH2 is functionally considered to suppress miR-31 expression in human cancers; however, no study has reported its relationship with colon cancer. We therefore evaluated EZH2 expression using immunohistochemistry and assessed miR-31 and epigenetic alterations using 301 colorectal carcinomas and 207 premalignant lesions. Functional analysis was performed to identify the association between EZH2 and miR-31 using cancer cell lines. In the current study, negative, weak, moderate, and strong EZH2 expressions were observed in 15{\%}, 19{\%}, 25{\%}, and 41{\%} of colorectal cancers, respectively. EZH2 was inversely associated with miR-31 (P <0.0001), independent of clinicopathological and molecular features. In a multivariate stage-stratified analysis, high EZH2 expression was related to favorable prognosis (P = 0.0022). Regarding premalignant lesions, negative EZH2 expression was frequently detected in sessile serrated adenomas/polyps (SSA/Ps) (76{\%}; P <0.0001) compared with hyperplastic polyps, traditional serrated adenomas, and non-serrated adenomas (25-36{\%}). Functional analysis demonstrated that the knockdown of EZH2 increased miR-31 expression. In conclusion, an inverse association was identified between EZH2 and miR-31 in colorectal cancers. Our data also showed that upregulation of EZH2 expression may be rare in SSA/Ps. These results suggest that EZH2 suppresses miR-31 in colorectal cancer and may correlate with differentiation and evolution of serrated pathway.",
keywords = "ChIP, CIMP, EGFR, EZH2, H3K27me3",
author = "Hiroyoshi Kurihara and Reo Maruyama and Kazuya Ishiguro and Shinichi Kanno and Itaru Yamamoto and Keisuke Ishigami and Kei Mitsuhashi and Hisayoshi Igarashi and Miki Ito and Tokuma Tanuma and Yasutaka Sukawa and Kenji Okita and Tadashi Hasegawa and Kohzoh Imai and Hiroyuki Yamamoto and Yasuhisa Shinomura and Katsuhiko Nosho",
year = "2016",
month = "3",
day = "15",
doi = "10.18632/oncotarget.7260",
language = "English",
volume = "7",
pages = "12704--12717",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "11",

}

TY - JOUR

T1 - The relationship between EZH2 expression and microRNA-31 in colorectal cancer and the role in evolution of the serrated pathway

AU - Kurihara, Hiroyoshi

AU - Maruyama, Reo

AU - Ishiguro, Kazuya

AU - Kanno, Shinichi

AU - Yamamoto, Itaru

AU - Ishigami, Keisuke

AU - Mitsuhashi, Kei

AU - Igarashi, Hisayoshi

AU - Ito, Miki

AU - Tanuma, Tokuma

AU - Sukawa, Yasutaka

AU - Okita, Kenji

AU - Hasegawa, Tadashi

AU - Imai, Kohzoh

AU - Yamamoto, Hiroyuki

AU - Shinomura, Yasuhisa

AU - Nosho, Katsuhiko

PY - 2016/3/15

Y1 - 2016/3/15

N2 - Polycomb group protein enhancer of zeste homolog 2 (EZH2) is a methyltransferase that correlates with the regulation of invasion and metastasis and is overexpressed in human cancers such as colorectal cancer. MicroRNA-31 (miR-31) plays an oncogenic role and is associated with BRAF mutation and poor prognosis in colorectal cancer. EZH2 is functionally considered to suppress miR-31 expression in human cancers; however, no study has reported its relationship with colon cancer. We therefore evaluated EZH2 expression using immunohistochemistry and assessed miR-31 and epigenetic alterations using 301 colorectal carcinomas and 207 premalignant lesions. Functional analysis was performed to identify the association between EZH2 and miR-31 using cancer cell lines. In the current study, negative, weak, moderate, and strong EZH2 expressions were observed in 15%, 19%, 25%, and 41% of colorectal cancers, respectively. EZH2 was inversely associated with miR-31 (P <0.0001), independent of clinicopathological and molecular features. In a multivariate stage-stratified analysis, high EZH2 expression was related to favorable prognosis (P = 0.0022). Regarding premalignant lesions, negative EZH2 expression was frequently detected in sessile serrated adenomas/polyps (SSA/Ps) (76%; P <0.0001) compared with hyperplastic polyps, traditional serrated adenomas, and non-serrated adenomas (25-36%). Functional analysis demonstrated that the knockdown of EZH2 increased miR-31 expression. In conclusion, an inverse association was identified between EZH2 and miR-31 in colorectal cancers. Our data also showed that upregulation of EZH2 expression may be rare in SSA/Ps. These results suggest that EZH2 suppresses miR-31 in colorectal cancer and may correlate with differentiation and evolution of serrated pathway.

AB - Polycomb group protein enhancer of zeste homolog 2 (EZH2) is a methyltransferase that correlates with the regulation of invasion and metastasis and is overexpressed in human cancers such as colorectal cancer. MicroRNA-31 (miR-31) plays an oncogenic role and is associated with BRAF mutation and poor prognosis in colorectal cancer. EZH2 is functionally considered to suppress miR-31 expression in human cancers; however, no study has reported its relationship with colon cancer. We therefore evaluated EZH2 expression using immunohistochemistry and assessed miR-31 and epigenetic alterations using 301 colorectal carcinomas and 207 premalignant lesions. Functional analysis was performed to identify the association between EZH2 and miR-31 using cancer cell lines. In the current study, negative, weak, moderate, and strong EZH2 expressions were observed in 15%, 19%, 25%, and 41% of colorectal cancers, respectively. EZH2 was inversely associated with miR-31 (P <0.0001), independent of clinicopathological and molecular features. In a multivariate stage-stratified analysis, high EZH2 expression was related to favorable prognosis (P = 0.0022). Regarding premalignant lesions, negative EZH2 expression was frequently detected in sessile serrated adenomas/polyps (SSA/Ps) (76%; P <0.0001) compared with hyperplastic polyps, traditional serrated adenomas, and non-serrated adenomas (25-36%). Functional analysis demonstrated that the knockdown of EZH2 increased miR-31 expression. In conclusion, an inverse association was identified between EZH2 and miR-31 in colorectal cancers. Our data also showed that upregulation of EZH2 expression may be rare in SSA/Ps. These results suggest that EZH2 suppresses miR-31 in colorectal cancer and may correlate with differentiation and evolution of serrated pathway.

KW - ChIP

KW - CIMP

KW - EGFR

KW - EZH2

KW - H3K27me3

UR - http://www.scopus.com/inward/record.url?scp=84962786545&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84962786545&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.7260

DO - 10.18632/oncotarget.7260

M3 - Article

C2 - 26871294

AN - SCOPUS:84962786545

VL - 7

SP - 12704

EP - 12717

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 11

ER -